SCHEMBL4006162

SCHEMBL4006162

NS(=O)(=O)c1cccc(Nc2nccc(-c3cccc(NC(=O)c4ccco4)c3)n2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MTOR P42345 8/20 0.58
CDK1 P06493 8/20 0.58
CDK2 P24941 6/20 0.58
PIK3CA P42336 1/20 0.58
PIK3CG P48736 1/20 0.58
SMG1 Q96Q15 7/20 0.55
MAPT P10636 2/20 0.54
MAPK1 P28482 2/20 0.54
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 2/20 0.53
KMT2A Q03164 2/20 0.53
MEN1 O00255 1/20 0.53
JAK2 O60674 1/20 0.53
HTT P42858 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
IKBKB O14920 2/20 0.52
SYK P43405 1/20 0.52
CYP1A2 P05177 1/20 0.52
GLA P06280 1/20 0.52
CYP3A4 P08684 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4003048 0.87 ABL1 (0.60) MAPTMAPK1KDM4EALDH1A1KMT2A
SCHEMBL4000098 0.85 PLK1 (0.59) MAPTMAPK1KDM4EALDH1A1KMT2A
SCHEMBL3999434 0.84 MAPK8 (0.66) MAPTMAPK1KDM4EALDH1A1KMT2A
SCHEMBL4004521 0.82 NPC1 (0.66) MTORPIK3CAPIK3CGSMG1MAPT
SCHEMBL6752978 0.80 CDK1 (0.66) MTORCDK1CDK2PIK3CAPIK3CG
SCHEMBL3997662 0.79 ABL1 (0.59) PIK3CGKMT2AMEN1JAK2ABL1
SCHEMBL6752979 0.79 CAMK2D (0.67) MTORCDK1CDK2PIK3CAPIK3CG
SCHEMBL7471938 0.78 ABL1 (0.70) MTORCDK1CDK2PIK3CAPIK3CG
SCHEMBL27116707 0.77 MAPT (0.57) MAPTMAPK1KDM4EALDH1A1KMT2A
SCHEMBL7524252 0.77 CDK1 (0.69) MTORCDK1CDK2PIK3CAPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2069314-A1 PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS CGI Pharmaceuticals, Inc. (US) 2009-06-17 EP claimed
US-20080125417-A1 CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. 2008-05-29 US claimed
WO-2008033834-A1 PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2008-03-20 WO claimed
EP-2069314-A1 PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS CGI Pharmaceuticals, Inc. (US) 2009-06-17 EP disclosed
US-20080125417-A1 CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF CGI PHARMACEUTICALS, INC. 2008-05-29 US disclosed
WO-2008033834-A1 PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS CGI PHARMACEUTICALS, INC. (US) 2008-03-20 WO disclosed
US-7312227-B2 Compositions useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-12-25 US disclosed
US-7312227-B2 Compositions useful as inhibitors of JAK and other protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-12-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125417-A1 CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF BTK, SYK, TK1 MTOR 1798/4885CDK1 221/4885CDK2 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.